Browse articles from EyeWorld.org related to crosslinking. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Results from Phase 2a study evaluating glaucoma drop ➤ Enrollment complete for epi-on crosslinking trial ➤ Phase 2 clinical trial begins for investigational dry eye drop ➤ Enrollment complete for Phase 2 study to evaluate diabetic retinopathy treatment ➤ Phase 2b trial for wet AMD treatment begins enrollment ➤ ASCRS news and events
➤ Alert: eye infections linked to artificial tear ➤ Phase 2 data from research targeting Sjogren’s treatment ➤ First patient dosed in Phase 1 study for epithelial defect treatment ➤ Study compares DMEK tissue preparation techniques ➤ Topline results from oral diabetic retinopathy treatment trial ➤ ASCRS news and events
➤ FDA approves new therapy for amblyopia ➤ First-in-human data from IOL/drug-delivery platform ➤ Largest crosslinking study to date for keratoconus ➤ Interim data for Phase 2 trial evaluating choroidal melanoma treatment ➤ Gene therapy update ➤ SLT trial seeking more clinical sites, deadline October 14 ➤ Acquisition news ➤ ASCRS news and events
“If there was ever a top 10 list of issues on which eyecare as a whole could ‘up its game,’ it should include the fact that we all need to be more aggressive about educating patients on the fact that they can create their own self-induced keratoconus by repetitive pressure on their eyes,” according to EyeWorld Refractive Editor Vance Thompson, MD.
With keratoconus, it’s important to diagnose patients as early as possible in order to treat them before more drastic procedures, like a corneal transplant, might be needed. Crosslinking has aided in the early treatment of keratoconus, and now, the use of genetic testing is another tool for doctors to add to their armamentarium.
➤ New 5-year data with MIGS device ➤ Phase 2 results with new epi-on crosslinking technology ➤ FDA grants IDE, authorizes trial of new viscodilation system ➤ Robotic surgery for glaucoma ➤ First patient dosed in Phase 3 trial of investigational drop for DME ➤ New glaucoma device approved in European market, plus Phase 2 results ➤ ASCRS news and events
➤ Controversies in cataract and refractive surgery ➤ Hot topics in ophthalmology ➤ Ophthalmic Premier League ➤ Management of retinal vasculitis
➤ Eyecelerator@AAO kicks off ➤ Digital health in ophthalmology ➤ Cornea spotlight ➤ Reimbursement ➤ Focused session on myopia ➤ Eyecelerator closes with awards and ‘eyes on the future’
While the Dresden protocol of epithelium removal, riboflavin loading, and UV light treatment remains the gold standard for crosslinking to stop progression of keratoconus, over the years there has been significant research on new techniques and adjuncts to enhance the effect, make the procedure less invasive, and/or expand its indications. One of these potential therapies for keratoconus still under investigation uses violet light-emitting glasses (KeraVio, Tsubota Laboratory).
➤ New visual prosthesis heads to clinical trial ➤ FDA grants Fast Track designation to investigational wet AMD therapy ➤ Patient enrollment complete in Phase 3 trial for investigational, first-in-class eye drop for DED ➤ FDA agrees to pivotal trial design for investigational treatment of geographic atrophy secondary to AMD ➤ ASCRS news and events